Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 6

Use of Trastuzumab Deruxtecan in Ovarian Cancer

, , , ,

Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, its potential impact on treating advanced ovarian cancer given HER2 data, and how T-DXd may fit into the current treatment algorithm for ovarian cancer.

Video content above is prompted by the following:

  • Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
  • Based on available HER2 data in ovarian cancer, what impact will this have on the treatment of advanced ovarian cancer?
  • Where do you see T-DXd fitting in your treatment algorithm for ovarian cancer?